Overview

Changes in Biomarkers Using Prostaglandin Inhibitors

Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
This is a biomarker study with the goal of measuring changes in proteins and gene methylation. This study is not intended for use in diagnosing, mitigating, treating, curing, or preventing disease. The purpose of this study is to determine if Vitamin D (cholecalciferol) alone and in combination with celecoxib (Celebrex, a non-steroidal anti-inflammatory drug, or NSAID), act together to decrease breast cancer risk by their effect on certain biological indicators (biomarkers) of breast cancer risk (called PGE2, COX-2, and 15-PGDH) and cell changes in the breast.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Hartford Hospital
Collaborator:
Susan G. Komen Breast Cancer Foundation
Treatments:
Celecoxib
Cholecalciferol
Vitamin D
Vitamins